Cediranib aims for a comeback.
Charlie
C
Schmidt
D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D000068258:Bevacizumab; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000139:chemically induced; D054547:National Cancer Institute (U.S.); D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010793:Phthalazines / Q000008:administration & dosage / Q000009:adverse effects*; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006113:United Kingdom; D014481:United States; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*; D014624:Vaginal Fistula / Q000139:chemically induced; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D015431:Weight Loss / Q000187:drug effects; D007211:Indoles
D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D010793:Phthalazines; D010879:Piperazines; D011505:Protein-Tyrosine Kinases; D011799:Quinazolines; D042461:Vascular Endothelial Growth Factor A; C467484:VEGFA protein, human; C500926:cediranib; D007211:Indoles; C531550:olaparib